Company Overview - Balchem Corporation is a leading provider of specialty ingredients and performance products, with over $1.0 billion in trailing twelve-month revenue and a diversified customer base [6] - The company utilizes advanced encapsulation and formulation technologies to deliver differentiated solutions for nutrition, health, and industrial markets [6] - Balchem's product portfolio includes microencapsulated nutrients, food and beverage systems, and sterilization agents, serving various sectors such as food, pharmaceuticals, and animal health [8] Financial Performance - For the year 2025, Balchem reported record net sales of $1 billion, an increase of 8.8%, and net earnings of $154.8 million, up 20.5% [10] - Adjusted EBITDA reached $274.9 million, and free cash flow hit a record $173.6 million [10] - The company maintained a gross margin of 35.6% in the fourth quarter despite input cost pressures [10] Market Position - As of February 17, 2026, Balchem's shares were priced at approximately $180, reflecting an 8% increase over the past year, which is lower than the S&P 500's 16% gain [7] - Balchem represents 1.6% of Harvey Partners' 13F reportable AUM of $1.13 billion, indicating a strategic addition to the fund's portfolio [7] - The company has a solid balance sheet, with cash at $74.6 million and net debt leverage at just 0.3 times adjusted EBITDA [11] Investment Appeal - The addition of Balchem to a portfolio primarily focused on cyclical industrial and equipment names provides a steady compounder with durable growth potential tied to nutrition and health trends [9][12] - The company's strong competitive position within the specialty chemicals sector is supported by its pricing power and recurring demand [12]